Landmark Ideas Series: Ray Kurzweil

Speaker: Ray Kurzweil, at Google and Kurzweil AI

Date: December 5, 2022 at 4:00PM - 5:00PM

Talk Topic: Rewriting Biology with Artificial Intelligence.

Ray Kurzweil is one of the world’s leading inventors, thinkers, and futurists, with a thirty-year track record of accurate predictions. Called "the restless genius" by The Wall Street Journal and "the ultimate thinking machine" by Forbesmagazine, he was selected as one of the top entrepreneurs by Inc. magazine, which described him as the "rightful heir to Thomas Edison." PBS selected him as one of the "sixteen revolutionaries who made America."

Ray was the principal inventor of the first CCD flat-bed scanner, the first omni-font optical character recognition, the first print-to-speech reading machine for the blind, the first text-to-speech synthesizer, the first music synthesizer capable of recreating the grand piano and other orchestral instruments, and the first commercially marketed large-vocabulary speech recognition software.

Ray received a Grammy Award for outstanding achievements in music technology; he is the recipient of the National Medal of Technology, was inducted into the National Inventors Hall of Fame, holds twenty-one honorary Doctorates, and honors from three U.S. presidents.


Ray has written five national best-selling books, including New York Times best sellers The Singularity Is Near (2005) and How To Create A Mind (2012).  He is Co-Founder of Singularity Group and a Principal Researcher and AI Visionary at Google, looking at the long-term implications of technology and society.


Publications

Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.